从哮喘成本到哮喘控制的经济效益
[Comment] From the cost of asthma to the economic dividends of asthma control
RSS 订阅 · The Lancet Respiratory Medicine
传统哮喘项目成功的衡量标准是减少症状、预防急性加重和降低死亡率。本文为评论文章，探讨哮喘控制的经济效益视角。
要点
- 有效疗法虽存在，但哮喘负担仍显著
- 哮喘项目传统评价指标为症状、急性加重和死亡率
核心结论
- 哮喘虽已有有效疗法，但仍造成显著疾病负担，需关注控制带来的经济效益
研究设计与样本
- 评论文章，无具体研究设计
主要发现
- 疾病负担包括持续症状、反复急性加重、生活质量受损、医疗资源使用和可预防死亡
临床怎么用
- 评价哮喘项目成功与否可考虑减少症状、预防急性加重和降低死亡率
以上解读依据论文摘要（全文未开放获取或许可不允许翻译转载）。
原文
Asthma affects more than 360 million people worldwide and remains one of the most common chronic diseases across the life course. Although effective therapies and evidence-based management strategies have transformed asthma care, the disease continues to impose a substantial burden through persistent symptoms, recurrent exacerbations, impaired quality of life, health-care use, and preventable deaths.1 Consequently, the success of asthma programmes has traditionally been measured by their ability to reduce symptoms, prevent exacerbations, and lower mortality.
来源：The Lancet Respiratory Medicine，查看原文。版权归原作者所有。
引用
- The Lancet Respiratory Medicine：[Comment] From the cost of asthma to the economic dividends of asthma control
供执业医师工作参考，不替代临床判断；数值与分级以指南原文为准。